The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 1, 2007, Pages 31-37

  Grigorescu, Mircea ^a   Rusu, Mihaela ^a   Neculoiu, Daniela ^a   Radu, Carina ^a   Şerban, Alexandru ^a   Caţanaş, Mihaela ^a   Grigorescu, Mircea Dan ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

FibroTest; Liver fibrosis; Serum biochemical markers

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; ROC CURVE;

ADULT; AGE FACTORS; ALGORITHMS; APOLIPOPROTEIN A-I; BILIRUBIN; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROMANIA; SERUM GLOBULINS; SEX FACTORS;

EID: 34047273737     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to injury. J Biol Chem 2000;275:2247-2250.
2. Schuppan D, Ruehl M, Somasundaran R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Sem in Liver Dis 2001;21:351-372.
3. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-1695.
4. Forns X, Ampurdanes S, Sanchez-Tapias JM, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001;35:265-271
5. Poynard T, McHutchinson J, Manns M,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 ; 122:1303-1313
6. Bedosa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
7. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Sem in Liver Dis 2004; 24:89-97.
8. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
9. Labayle D, Chaput JC, Albuisson F, Buffet C, Martin E, Etienne JP. Comparison of the histological lesions in tissue specimens taken from the right and left lobe of the liver in alcoholic liver disease. Gastroenterol Clin Biol 1979; 3:235-240.
10. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-525.
11. Ratziu V, Charlotte F, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
12. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 127:1704-1713.
13. Pradat P, Alberti A, Poynard T et al. Predictive value of ALT values for histologic findings in chronic hepatitis C: a European Collaborative Study. Hepatology 2002; 36:973-977.
14. Giannini E, Risso D, Botta F et al. Validity and clinical utility of aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224.
15. Peck-Radoslavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13:317-323.
16. Croquet V, Vuillemin E, Ternisien C et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002; 14:1133-1141.
17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis. Hepatology 2003; 38:518-526.
18. Teare JP, Sherman D, Greenfield SM et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342:895-898.
19. Naveau S, Poynard T, Benattar C et al. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994; 39:2426-2432.
20. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
21. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis on patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
22. Halfon P, Bourliere M, Deydier R et al. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterol 2006; 101: 547-555.
23. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-230.
24. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-531.
25. Naveau S, Raynard B, Ratziu V, et al. The diagnostic value of biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167-174.
26. Ratziu V, Le Calvez S, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (Fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology 2003;38:510A.
27. Ngo Y, Munteanu M, Messous D, et all. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-1896
28. Website of the French Health Authority (La Haute Autorité de Santé-HAS)http://www.has-sante.fr/portail/display.jsp?id=c_476347
29. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-1355.
30. Bedosa P, Poynard T. An algorithm for the grading of the activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
31. Desmet VJ. Milestones in liver disease: Scoring chronic hepatitis. J Hepatol 2003; 38: 382-386.
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845.
33. Zhou X, Obuchowski N, McClish D. Statistical methods in diagnostic medicine. John Wiley and Sons, New York: 2002.
34. Poynard T, Halfon P, Castera L, et al. FibroPaca group. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007; 25: 733-39
35. Poynard T, Imbert-Bismut F, Ratziu V et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepatitis 2002; 9:128-138.
36. Myers RP, de Torres M, Imbert-Bismut F et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and age-platelet index. Dig Dis Sci 2003; 48:146-153.
37. Thabut D, Simon M, Myers RP et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37:1220-1221.
38. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997; 181: 257-266.
39. Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV. The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on inteleukin-6-stimulated genes. Hepatology 1996; 23: 1345-1352.
40. Kawser CA, Iredale JP, Winwood PJ, Arthur MJP. Rat hepatic stellate cell expression of á2 macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci 1998; 95:179-186.
41. Bacq Y, Schillio Y, Brechot JF et al. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 1993; 17:364-369.
42. Paradis V, Mathurin P, Ratziu V et al. Binding of apolipoprotein A1 and acetaldehyde-modified apoliproteinA1 to liver extracellular matrix. Hepatology 1996; 23: 1232-1238.
43. Poynard T, Bedosa P, Mathurin P et al. Apolipoprotein A1 and hepatic fibrosis. J Hepatol 1995; 22: 107-110.
44. Hinoshita E, Taguchi K, Inokuchi A et al. Decreased expression of an ATP-binding cassette transporter, MRP2 in human livers with hepatitis C virus infection. J Hepatol 2001; 35:765-773.
45. Edwards AM, Lucas CM, Baddams HM. Modulation of gamma-glutamyl transpepetidase in normal rat hepatocytes in culture by cell density, epidermal growth factor and agents which alter cell differentiation. Carcinogenesis 1987; 8:1837-1842.
46. Myers RP, Ratziu V, Imbert-Bismut F et al. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis. Am J Gastroenterol 2002; 97: 2419-2425.
47. Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hep 2004; 3:8.
48. Rossi E, Adams L, Prins A et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49:450-454.
49. Leroy V, Hilleret MN, Strum N et al. Are current fibrosis serum markers really an alternation to liver biopsy in chronic hepatitis C? J Hepatol 2005; 42:210 (Abstr).
50. Rosenthal-Allieri MA, Peritore ML, Tran A et al. Analytical variability of the FibroTest proteins. Clin Biochem 2005; 38: 473-478.
51. Piton A, Messous D, Imbert-Bismut F, et al. Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analyzers (Modular P, Cobas Integra). Application to FibroTest-ActiTest (FT-AT). Ann Biol Clin 2005; 63: 385-95.